Treatment with low doses of cabergoline is not associated with increased prevalence of cardiac valve regurgitation in patients with hyperprolactinaemia
Identifieur interne : 000C35 ( Main/Exploration ); précédent : 000C34; suivant : 000C36Treatment with low doses of cabergoline is not associated with increased prevalence of cardiac valve regurgitation in patients with hyperprolactinaemia
Auteurs : F. Bogazzi [Italie] ; S. Buralli [Italie] ; L. Manetti [Italie] ; V. Raffaelli [Italie] ; T. Cigni [Italie] ; M. Lombardi [Italie] ; F. Boresi [Italie] ; S. Taddei [Italie] ; A. Salvetti [Italie] ; E. Martino [Italie]Source :
- International Journal of Clinical Practice [ 1368-5031 ] ; 2008-12.
Abstract
Introduction and aim: Dopamine agonists have been reported to increase the risk of cardiac valve regurgitation in patients with Parkinson’s disease. However, it is unknown whether these drugs might be harmful for patients with hyperprolactinaemia (HyperPRL). The aim of the study was to evaluate whether HyperPRL patients treated with dopamine agonists had a higher prevalence of cardiac valves regurgitation than that of general population. Methods and patients: One hundred consecutive patients (79 women, 21 men, mean age 41 ± 13 years) with HyperPRL during treatment with cabergoline were enrolled in an observational case–control study and compared with 100 matched normal subjects (controls). Valve regurgitation was assessed by echocardiography according to the American Society of Echocardiography recommendations. Results: Seven HyperPRL patients (7%) and six controls (6%) had moderate (grade 3) regurgitation in any valve (p = 0.980). All were asymptomatic and had no signs of cardiac disease. Mean duration of cabergoline treatment was 67 ± 39 months (range: 3–199 months). Mean cumulative dose of cabergoline was 279 ± 301 mg (range: 15–1327 mg). Moderate valve regurgitation was not associated with the duration of treatment (p = 0.359), with cumulative dose of cabergoline (p = 0.173), with age (p = 0.281), with previous treatment with bromocriptine (p = 0.673) or previous adenomectomy (p = 0.497) in patients with HyperPRL. Discussion: In conclusion, treatment with cabergoline was not associated with increased prevalence of cardiac valves regurgitation in patients with HyperPRL. Mean cumulative dose of cabergoline was lower in patients with HyperPRL than that reported to be deleterious for patients with Parkinson’s disease: hence, longer follow‐up is necessary, particularly in patients receiving weekly doses > 3 mg.
Url:
DOI: 10.1111/j.1742-1241.2008.01779.x
Affiliations:
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Treatment with low doses of cabergoline is not associated with increased prevalence of cardiac valve regurgitation in patients with hyperprolactinaemia</title><author><name sortKey="Bogazzi, F" sort="Bogazzi, F" uniqKey="Bogazzi F" first="F." last="Bogazzi">F. Bogazzi</name></author><author><name sortKey="Buralli, S" sort="Buralli, S" uniqKey="Buralli S" first="S." last="Buralli">S. Buralli</name></author><author><name sortKey="Manetti, L" sort="Manetti, L" uniqKey="Manetti L" first="L." last="Manetti">L. Manetti</name></author><author><name sortKey="Raffaelli, V" sort="Raffaelli, V" uniqKey="Raffaelli V" first="V." last="Raffaelli">V. Raffaelli</name></author><author><name sortKey="Cigni, T" sort="Cigni, T" uniqKey="Cigni T" first="T." last="Cigni">T. Cigni</name></author><author><name sortKey="Lombardi, M" sort="Lombardi, M" uniqKey="Lombardi M" first="M." last="Lombardi">M. Lombardi</name></author><author><name sortKey="Boresi, F" sort="Boresi, F" uniqKey="Boresi F" first="F." last="Boresi">F. Boresi</name></author><author><name sortKey="Taddei, S" sort="Taddei, S" uniqKey="Taddei S" first="S." last="Taddei">S. Taddei</name></author><author><name sortKey="Salvetti, A" sort="Salvetti, A" uniqKey="Salvetti A" first="A." last="Salvetti">A. Salvetti</name></author><author><name sortKey="Martino, E" sort="Martino, E" uniqKey="Martino E" first="E." last="Martino">E. Martino</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:6EFF6427F5E1CE040983D561001D0FD65B3255D9</idno><date when="2008" year="2008">2008</date><idno type="doi">10.1111/j.1742-1241.2008.01779.x</idno><idno type="url">https://api.istex.fr/document/6EFF6427F5E1CE040983D561001D0FD65B3255D9/fulltext/pdf</idno><idno type="wicri:Area/Main/Corpus">002E52</idno><idno type="wicri:Area/Main/Curation">002A69</idno><idno type="wicri:Area/Main/Exploration">000C35</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Treatment with low doses of cabergoline is not associated with increased prevalence of cardiac valve regurgitation in patients with hyperprolactinaemia</title><author><name sortKey="Bogazzi, F" sort="Bogazzi, F" uniqKey="Bogazzi F" first="F." last="Bogazzi">F. Bogazzi</name><affiliation wicri:level="1"><country xml:lang="fr">Italie</country><wicri:regionArea>Department of Endocrinology and Metabolism, University of Pisa, Pisa</wicri:regionArea><wicri:noRegion>Pisa</wicri:noRegion></affiliation></author><author><name sortKey="Buralli, S" sort="Buralli, S" uniqKey="Buralli S" first="S." last="Buralli">S. Buralli</name><affiliation wicri:level="1"><country xml:lang="fr">Italie</country><wicri:regionArea>Department of Internal Medicine, University of Pisa, Pisa</wicri:regionArea><wicri:noRegion>Pisa</wicri:noRegion></affiliation></author><author><name sortKey="Manetti, L" sort="Manetti, L" uniqKey="Manetti L" first="L." last="Manetti">L. Manetti</name><affiliation wicri:level="1"><country xml:lang="fr">Italie</country><wicri:regionArea>Department of Endocrinology and Metabolism, University of Pisa, Pisa</wicri:regionArea><wicri:noRegion>Pisa</wicri:noRegion></affiliation></author><author><name sortKey="Raffaelli, V" sort="Raffaelli, V" uniqKey="Raffaelli V" first="V." last="Raffaelli">V. Raffaelli</name><affiliation wicri:level="1"><country xml:lang="fr">Italie</country><wicri:regionArea>Department of Endocrinology and Metabolism, University of Pisa, Pisa</wicri:regionArea><wicri:noRegion>Pisa</wicri:noRegion></affiliation></author><author><name sortKey="Cigni, T" sort="Cigni, T" uniqKey="Cigni T" first="T." last="Cigni">T. Cigni</name><affiliation wicri:level="1"><country xml:lang="fr">Italie</country><wicri:regionArea>Department of Endocrinology and Metabolism, University of Pisa, Pisa</wicri:regionArea><wicri:noRegion>Pisa</wicri:noRegion></affiliation></author><author><name sortKey="Lombardi, M" sort="Lombardi, M" uniqKey="Lombardi M" first="M." last="Lombardi">M. Lombardi</name><affiliation wicri:level="1"><country xml:lang="fr">Italie</country><wicri:regionArea>Department of Endocrinology and Metabolism, University of Pisa, Pisa</wicri:regionArea><wicri:noRegion>Pisa</wicri:noRegion></affiliation></author><author><name sortKey="Boresi, F" sort="Boresi, F" uniqKey="Boresi F" first="F." last="Boresi">F. Boresi</name><affiliation wicri:level="1"><country xml:lang="fr">Italie</country><wicri:regionArea>Department of Internal Medicine, University of Pisa, Pisa</wicri:regionArea><wicri:noRegion>Pisa</wicri:noRegion></affiliation></author><author><name sortKey="Taddei, S" sort="Taddei, S" uniqKey="Taddei S" first="S." last="Taddei">S. Taddei</name><affiliation wicri:level="1"><country xml:lang="fr">Italie</country><wicri:regionArea>Department of Internal Medicine, University of Pisa, Pisa</wicri:regionArea><wicri:noRegion>Pisa</wicri:noRegion></affiliation></author><author><name sortKey="Salvetti, A" sort="Salvetti, A" uniqKey="Salvetti A" first="A." last="Salvetti">A. Salvetti</name><affiliation wicri:level="1"><country xml:lang="fr">Italie</country><wicri:regionArea>Department of Internal Medicine, University of Pisa, Pisa</wicri:regionArea><wicri:noRegion>Pisa</wicri:noRegion></affiliation></author><author><name sortKey="Martino, E" sort="Martino, E" uniqKey="Martino E" first="E." last="Martino">E. Martino</name><affiliation wicri:level="1"><country xml:lang="fr">Italie</country><wicri:regionArea>Department of Endocrinology and Metabolism, University of Pisa, Pisa</wicri:regionArea><wicri:noRegion>Pisa</wicri:noRegion></affiliation></author></analytic><monogr></monogr><series><title level="j">International Journal of Clinical Practice</title><idno type="ISSN">1368-5031</idno><idno type="eISSN">1742-1241</idno><imprint><publisher>Blackwell Publishing Ltd</publisher><pubPlace>Oxford, UK</pubPlace><date type="published" when="2008-12">2008-12</date><biblScope unit="volume">62</biblScope><biblScope unit="issue">12</biblScope><biblScope unit="page" from="1864">1864</biblScope><biblScope unit="page" to="1869">1869</biblScope></imprint><idno type="ISSN">1368-5031</idno></series><idno type="istex">6EFF6427F5E1CE040983D561001D0FD65B3255D9</idno><idno type="DOI">10.1111/j.1742-1241.2008.01779.x</idno><idno type="ArticleID">IJCP1779</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">1368-5031</idno></seriesStmt></fileDesc><profileDesc><textClass></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Introduction and aim: Dopamine agonists have been reported to increase the risk of cardiac valve regurgitation in patients with Parkinson’s disease. However, it is unknown whether these drugs might be harmful for patients with hyperprolactinaemia (HyperPRL). The aim of the study was to evaluate whether HyperPRL patients treated with dopamine agonists had a higher prevalence of cardiac valves regurgitation than that of general population. Methods and patients: One hundred consecutive patients (79 women, 21 men, mean age 41 ± 13 years) with HyperPRL during treatment with cabergoline were enrolled in an observational case–control study and compared with 100 matched normal subjects (controls). Valve regurgitation was assessed by echocardiography according to the American Society of Echocardiography recommendations. Results: Seven HyperPRL patients (7%) and six controls (6%) had moderate (grade 3) regurgitation in any valve (p = 0.980). All were asymptomatic and had no signs of cardiac disease. Mean duration of cabergoline treatment was 67 ± 39 months (range: 3–199 months). Mean cumulative dose of cabergoline was 279 ± 301 mg (range: 15–1327 mg). Moderate valve regurgitation was not associated with the duration of treatment (p = 0.359), with cumulative dose of cabergoline (p = 0.173), with age (p = 0.281), with previous treatment with bromocriptine (p = 0.673) or previous adenomectomy (p = 0.497) in patients with HyperPRL. Discussion: In conclusion, treatment with cabergoline was not associated with increased prevalence of cardiac valves regurgitation in patients with HyperPRL. Mean cumulative dose of cabergoline was lower in patients with HyperPRL than that reported to be deleterious for patients with Parkinson’s disease: hence, longer follow‐up is necessary, particularly in patients receiving weekly doses > 3 mg.</div></front></TEI><affiliations><list><country><li>Italie</li></country></list><tree><country name="Italie"><noRegion><name sortKey="Bogazzi, F" sort="Bogazzi, F" uniqKey="Bogazzi F" first="F." last="Bogazzi">F. Bogazzi</name></noRegion><name sortKey="Boresi, F" sort="Boresi, F" uniqKey="Boresi F" first="F." last="Boresi">F. Boresi</name><name sortKey="Buralli, S" sort="Buralli, S" uniqKey="Buralli S" first="S." last="Buralli">S. Buralli</name><name sortKey="Cigni, T" sort="Cigni, T" uniqKey="Cigni T" first="T." last="Cigni">T. Cigni</name><name sortKey="Lombardi, M" sort="Lombardi, M" uniqKey="Lombardi M" first="M." last="Lombardi">M. Lombardi</name><name sortKey="Manetti, L" sort="Manetti, L" uniqKey="Manetti L" first="L." last="Manetti">L. Manetti</name><name sortKey="Martino, E" sort="Martino, E" uniqKey="Martino E" first="E." last="Martino">E. Martino</name><name sortKey="Raffaelli, V" sort="Raffaelli, V" uniqKey="Raffaelli V" first="V." last="Raffaelli">V. Raffaelli</name><name sortKey="Salvetti, A" sort="Salvetti, A" uniqKey="Salvetti A" first="A." last="Salvetti">A. Salvetti</name><name sortKey="Taddei, S" sort="Taddei, S" uniqKey="Taddei S" first="S." last="Taddei">S. Taddei</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000C35 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000C35 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:6EFF6427F5E1CE040983D561001D0FD65B3255D9
|texte= Treatment with low doses of cabergoline is not associated with increased prevalence of cardiac valve regurgitation in patients with hyperprolactinaemia
}}
| This area was generated with Dilib version V0.6.23. |  |